Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.55 |
| ▸ | CES1 | P23141 | 2/20 | 0.55 |
| ▸ | PARP1 | P09874 | 1/20 | 0.52 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL726429 | 1.00 | CES2 (0.55) | CES2CES1PARP1GPR52HDAC6 | |
| SCHEMBL726756 | 1.00 | CES2 (0.55) | CES2CES1PARP1GPR52HDAC6 | |
| SCHEMBL3305320 | 0.81 | CES2 (0.48) | CES2CES1PARP1GPR52HPGD | |
| SCHEMBL3305322 | 0.81 | CES2 (0.48) | CES2CES1PARP1GPR52HPGD | |
| SCHEMBL3305324 | 0.81 | CES2 (0.48) | CES2CES1PARP1GPR52HPGD | |
| SCHEMBL6206435 | 0.80 | CA12 (0.57) | PARP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6206438 | 0.80 | CA12 (0.57) | PARP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL6205576 | 0.80 | CA12 (0.57) | PARP1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL29089444 | 0.79 | PARP1 (0.58) | CES2CES1PARP1GPR52HDAC6 | |
| SCHEMBL8090077 | 0.79 | LMNA (0.50) | CES2CES1PARP1GPR52MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4813800-B2 | — | — | 2011-11-09 | — | — | JP | claimed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | claimed |
| EP-1581215-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GmbH (DE) | 2005-10-05 | — | — | EP | claimed |
| WO-2004060369-A1 | KYNURENINE 3-HYDROXYLASE INHIBITORS FOR THE TREATMENT OF DIABETES | MERCK PATENT GMBH (DE) | 2004-07-22 | — | — | WO | claimed |
| US-9737522-B2 | NMDA receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| US-20150196540-A1 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2015-07-16 | — | — | US | disclosed |
| WO-2014025942-A1 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO | EMORY UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| US-7727977-B2 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-06-01 | — | — | US | disclosed |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2006-06-29 | — | — | US | disclosed |
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | MERCK PATENT GMBH (DE) | 2006-03-09 | — | — | US | disclosed |
| US-6048896-A | FOR TREATMENT OF BRAIN OR NERVOUS SYSTEM DISORDERS | PHARMACIA & UPJOHN S.P.A. (IT) | 2000-04-11 | — | — | US | disclosed |
| EP-0858442-A1 | 4-PHENYL-4-OXO-2-BUTENOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-08-19 | — | — | EP | disclosed |
| WO-1997017316-A1 | 4-PHENYL-4-OXO-2-BUTENOIC ACID DERIVATIVES WITH KYNURENINE-3-HYDROXYLASE INHIBITING ACTIVITY | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052456-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes by increasing the number of islets of langerhans cells | KYNU, KMO, IDO1 | CES2 2432/4885CES1 508/4885PARP1 2849/4885 |
| US-20150196540-A1 | NMDA RECEPTOR MODULATORS AND USES RELATED THERETO | GRIN2C, GRIN2A, GRIN3A | CES2 1220/4885CES1 3790/4885PARP1 2202/4885 |
| US-20060142358-A1 | Kynurenine 3-hydroxylase inhibitors for the treatment of diabetes | KYNU, KMO, AADAT | CES2 1270/4885CES1 249/4885PARP1 2313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.